The role of Tumor Necrosis Factor -Alpha (TNF-α) in bone resorption present in middle ear cholesteatoma

Summary Cholesteatoma may cause bone erosion, with high morbidity and mortality rates. Tumor Necrosis Factor - Alpha (TNF-a) is one of the main cytokines involved in this process. Our goal was to evaluate the role of TNF-a in Bone Resorption and its effect on cholesteatoma. Material and Methods analysis and critical literature review. Results Different studies have demonstrated that TNF-a is capable of causing bone erosion. It may stimulate the differentiation and maturation of osteoclasts or it may act on the bone matrix, exposing it to the action of the osteoclasts. It is possible to inhibit TNF-a, reducing its effects and prevent bone loss in illnesses such as rheumatoid arthritis, and there has been no specific investigation regarding cholesteatomas. All studies agree on the importance of TNF-a in the bone resorption process present in cholesteatomas, and on the degree of destruction observed; however, there is no consensus as to its location. These differences are probably due to receptor site. Conclusion TNF-a, present in cholesteatomas, promotes bone resorption, along with other cytokines (RANKL and IL-1) related to complications.

[1]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[2]  N. Panda,et al.  Aural cholesteatoma: role of tumor necrosis factor-alpha in bone destruction. , 1999, The American journal of otology.

[3]  J. Dayer,et al.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. , 1989, The Journal of biological chemistry.

[4]  G. Leonard,et al.  Characterization of cytokines present in middle ear effusions , 1991, The Laryngoscope.

[5]  J. Chung,et al.  Different Production of Interleukin-1a, Interleukin-1ß and Interleukin-8 from Cholesteatomatous and Normal Epithelium , 1998 .

[6]  M. Kawakami,et al.  Cholesteatoma debris as an activator of human monocytes. Potentiation of the production of tumor necrosis factor. , 1990, Acta oto-laryngologica.

[7]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Amar,et al.  Clinical and biochemical studies of bone destruction in cholesteatoma , 1996, The Journal of Laryngology & Otology.

[9]  A. Mukherjee,et al.  Tumor Necrosis Factor-α (TNF) Stimulates RANKL-induced Osteoclastogenesis via Coupling of TNF Type 1 Receptor and RANK Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[10]  S. D. Yan,et al.  The role of tumor necrosis factor-alpha in bone resorption of cholesteatoma. , 1991, American journal of otolaryngology.

[11]  Fernando de Andrade Quintanilha Ribeiro,et al.  O papel das citocinas no colesteatoma adquirido da orelha média: revisão da literatura , 2004 .

[12]  S. Goldring.  Pathogenesis of bone erosions in rheumatoid arthritis. , 2002, Current opinion in rheumatology.

[13]  B. Satar,et al.  Expression of Epidermal Growth Factor, Tumor Necrosis Factor-&agr;, and Interleukin-1&agr; in Chronic Otitis Media with or without Cholesteatoma , 2002 .

[14]  S. Goldring.  Bone and joint destruction in rheumatoid arthritis: what is really happening? , 2002, The Journal of rheumatology. Supplement.

[15]  S. Yeo,et al.  Effect of Inhibitor of Tumor Necrosis Factor-Alpha on Experimental Otitis Media with Effusion , 2001, The Annals of otology, rhinology, and laryngology.

[16]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[17]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[18]  D. Graves,et al.  IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. , 1998, Journal of immunology.

[19]  Clifton O Bingham,et al.  The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. , 2002, The Journal of rheumatology. Supplement.

[20]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[21]  R. Pawankar,et al.  Acquired and Congenital Cholesteatoma: Determination of Tumor Necrosis Factor-alpha, Intercellular Adhesion Molecule-1, Interleukin-1-alpha and Lymphocyte Functional Antigen-1 in the Inflammatory Process , 2000, ORL.

[22]  E. Nilsson,et al.  Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.